Chemotherapy in patients with renal failure, dialysis and transplantation;Chemotherapie bei patienten mit niereninsuffizienz, dialyse und nach transplantation

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 36, 2005, Pages 2043-2046

  Rasche, F M ^a   Keller, Frieder ^a   Czock, D ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYSTATIN C; CYTARABINE; CYTOSTATIC AGENT; DACARBAZINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; IFOSFAMIDE; INSULIN; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; NAVELBINE; PROCARBAZINE; TIOGUANINE; UNINDEXED DRUG; VINCRISTINE;

CANCER CHEMOTHERAPY; DIALYSIS; DRUG CONTRAINDICATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NOTE; PHARMACODYNAMICS; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NEOPLASMS; RENAL DIALYSIS; RISK FACTORS;

EID: 24944565193     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-872628     Document Type: Note

References (10)

1. Agraharkar ML, Cinclair RD, Kuo YF, Daller JA, Shahinian VB. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int 2004; 66: 383-389
2. Boesler B, Czock D, Keller F, Griesshammer M, Seufferlein T, Karges W, Rasche FM. Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy. Nephrol Dial Transplant 2005; 20: 1187-1191
3. Casserly LF, Fadia A, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int 2003; 63: 1051-1057
4. Dettli L. Drug dosage in renal disease. Clin Pharmacokinet 1976; 1: 126-134
5. Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002; 61: 1495-1501
6. Inoue A, Saijo Y, Kikuchi T, Gomi K, Suzuki T, Maemondo M, Miki M, Sato T, Nukiwa T. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol 2004; 15: 51-54
7. Keller F, Frankewitsch T, Zellner D, Simon S, Czock D, Giehl M. Standardized structure and modular design of a pharmacokinetic database. Comput Methods Programs Biomed 1998; 55: 107-115
8. Lohr JW, Willsky GR, Acara MA. Renal drug metabolism. Pharmacol Rev 1998; 50: 107-141
9. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-99
10. Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, Ronco P, Brauet JC, Fermand JP. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004; 65: 642-648